Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek J. Maetzold sold 1,972 shares of the business's stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $31.35, for a total value of $61,822.20. Following the transaction, the insider now directly owns 85,748 shares of the company's stock, valued at $2,688,199.80. This represents a 2.25 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Castle Biosciences Stock Performance
NASDAQ CSTL opened at $30.91 on Tuesday. The stock has a market cap of $865.70 million, a P/E ratio of 154.55 and a beta of 0.92. The company has a quick ratio of 7.64, a current ratio of 7.78 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a twelve month low of $16.97 and a twelve month high of $35.84. The company's 50-day simple moving average is $31.19 and its 200 day simple moving average is $26.95.
Castle Biosciences (NASDAQ:CSTL - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.14. The company had revenue of $85.78 million for the quarter, compared to analyst estimates of $78.55 million. Castle Biosciences had a return on equity of 1.47% and a net margin of 1.95%. During the same period in the prior year, the company posted ($0.26) EPS. As a group, research analysts forecast that Castle Biosciences, Inc. will post 0.34 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Did You See Trump’s Bombshell Exec. Order 001?
From Banyan Hill Publishing | Ad
Starting with what I call Exec. Order 001.
It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...
I put all the details together for you here — but please hurry.
Hedge funds have recently bought and sold shares of the stock. Quest Partners LLC grew its holdings in shares of Castle Biosciences by 54.4% in the 3rd quarter. Quest Partners LLC now owns 4,318 shares of the company's stock worth $123,000 after purchasing an additional 1,522 shares during the last quarter. US Bancorp DE boosted its position in Castle Biosciences by 1,889.2% in the third quarter. US Bancorp DE now owns 4,615 shares of the company's stock valued at $132,000 after buying an additional 4,383 shares in the last quarter. Point72 DIFC Ltd acquired a new position in Castle Biosciences in the third quarter valued at about $140,000. Assetmark Inc. grew its stake in Castle Biosciences by 16.8% during the third quarter. Assetmark Inc. now owns 5,212 shares of the company's stock worth $149,000 after buying an additional 748 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Castle Biosciences by 64.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,335 shares of the company's stock worth $152,000 after buying an additional 2,093 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
CSTL has been the topic of several recent analyst reports. Lake Street Capital lifted their price target on Castle Biosciences from $34.00 to $40.00 and gave the stock a "buy" rating in a research report on Tuesday, November 5th. Canaccord Genuity Group upped their target price on shares of Castle Biosciences from $35.00 to $42.00 and gave the company a "buy" rating in a research note on Tuesday, October 29th. Robert W. Baird increased their price target on shares of Castle Biosciences from $37.00 to $39.00 and gave the company an "outperform" rating in a report on Tuesday, November 5th. KeyCorp boosted their price objective on shares of Castle Biosciences from $28.00 to $36.00 and gave the stock an "overweight" rating in a report on Tuesday, November 5th. Finally, BTIG Research increased their target price on shares of Castle Biosciences from $35.00 to $40.00 and gave the company a "buy" rating in a research note on Monday, October 14th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Castle Biosciences has a consensus rating of "Buy" and an average target price of $37.88.
Read Our Latest Report on Castle Biosciences
About Castle Biosciences
(
Get Free Report)
Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
